STRO
SUTRO BIOPHARMA, INC.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeSutro reported a significant 85% year-over-year revenue decline ($9.8M vs $63.7M) and missed EPS expectations in Q2 2026, driven by lower collaboration revenue. However, the company maintains a strong cash position of $164.3M (runway to Q2 2028) and reported encouraging early clinical data for STRO-004, with continued progress on wholly-owned pipeline programs including STRO-227 and Astellas-partnered assets.
Red flags
- •Q2 2026 revenue declined 85% year-over-year ($9.8M vs $63.7M), indicating major loss of collaboration revenue
- •EPS of -$2.33 missed analyst expectations
- •High burn rate of $39.5M in quarterly R&D and G&A expenses relative to revenue generation
- •Stock trading 40–45% below 52-week high ($23–26 vs $43.85), reflecting loss of investor confidence post-earnings
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).